This article is more than 5 years old. Information may no longer be current.
Cardiology Today's Intervention top 5 articles posted in October
Click Here to Manage Email Alerts
Cardiology Today’s Intervention compiled a list of the top 5 stories posted to Healio.com/Intervention in October.
This month, Cardiology Today’s Intervention readers were most interested in use of a percutaneous system vs. surgical cutdown for access-site closure, venous disease treatment efficacy, results of the CULPRIT-SHOCK study, self-expanding prosthesis in transcatheter aortic valve replacement, moderate paravalvular regurgitation and much more.
Percutaneous system for access-site closure beneficial vs. surgical cutdown
LAS VEGAS — Percutaneous closure of large-bore arterial access sites was associated with positive outcomes compared with surgical cutdown, according to data presented at VIVA 17.
The percutaneous closure device (Perclose ProGlide, Abbott Vascular) was associated with fewer blood transfusions and infections, lower mortality and shorter length of stay compared with surgical cutdown, Darren Schneider, MD, associate professor and chief of vascular and endovascular surgery at the NewYork-Presbyterian/Weill Cornell Medical Center and Weill Cornell Medicine, said here.
Effectiveness evidence poor for venous disease treatments
Evidence was not strong enough to adequately compare endovascular interventions and endovascular vs. other interventions in patients with lower-extremity venous conditions, according to a report in the American Heart Journal.
As Cardiology Today’s Intervention previously reported, a Medicare Evidence Development and Coverage Advisory Committee (MEDCAC) panel had low confidence that there is sufficient evidence for interventions for many classes of patients with venous disease.
CULPRIT-SHOCK: Culprit lesion only may be superior to immediate multivessel PCI
The 30-day risk for composite death or severe renal failure leading to renal-replacement therapy in patients with multivessel CAD and acute MI with cardiogenic shock was lower among those who underwent PCI of the culprit lesion only compared with those who received immediate multivessel PCI, according to the results of the CULPRIT-SHOCK trial, presented at TCT 2017.
The study results, presented by Holger Thiele, MD, from the Heart Center Leipzig and the University Hospital, Leipzig, Germany, were simultaneously published in The New England Journal of Medicine.
Newer self-expanding prosthesis associated with improved clinical success in TAVR
A newer-generation self-expanding prosthesis has been linked to improvements in clinical success for patients undergoing TAVR for aortic stenosis, according to data published in JACC: Cardiovascular Interventions.
The researchers also found the newer self-expanding prosthesis (Evolut R platform, Medtronic) was associated with a lower rate of mortality than Medtronic’s earlier-generation CoreValve prosthesis.
Moderate paravalvular regurgitation may increase 1-year mortality rates
Moderate or severe paravalvular regurgitation, although rare, is linked to a significantly increased risk for mortality and HF rehospitalization at 1 year in patients undergoing TAVR, according to new data from the PARTNER II SAPIEN 3 trial.
“Studies have shown that TAVR is equivalent to surgical aortic valve replacement in patients at intermediate surgical risk,” Philippe Pibarot, DVM, PhD, from the Institut Universitaire de Cardiologie et de Pneumologie de Québec, and colleagues wrote. “However, paravalvular regurgitation is an important complication of TAVR that has been shown to be associated with increase mortality for both the balloon-expandable and the self-expanding transcatheter heart valves.”